A side-by-side comparison of two Healthcare investors: Deerfield Management (Power Score 83/100) and Shenzhen Capital Group (Power Score 80/100), both ranked among the most active firms tracked in this category.
| Deerfield Management | Shenzhen Capital Group | |
|---|---|---|
| Power Score™ | 83/100 | 80/100 |
| Assets Managed | More than $16B (in assets as of December 2025, per the firm's own About page; the figure could not be checked against Form ADV Item 5.F) | US$50B+ (approx.; the firm's figure is RMB 360.273bn of paid-in capital across all funds it and its subsidiaries manage at 31 December 2024, per its 2025 bond credit rating report - paid-in fund scale, not net asset value) |
| Founded | 1994 | 1999 |
| Headquarters | New York, NY | Shenzhen, China |
| Sectors | Therapeutics, Medical Devices, Healthcare, Diagnostics, Digital Health, Life Sciences | Semiconductors, Technology, Robotics, Industrial Manufacturing, Advanced Manufacturing, Clean Energy, Biotech, Pharmaceuticals, Infrastructure Software |
Deerfield describes itself as an investment firm dedicated to advancing healthcare through investment, intelligence and philanthropy, and says it holds a portfolio of more than two hundred private and public investments spanning therapeutics, medical devices, healthcare services, diagnostics and digital health. It states that it invests across capital structures and across company stages, from early-stage startups to mature companies, and that it offers structured finance solutions and customised financing for entrepreneurs and corporate partners in both public and private markets. Alongside the funds it runs an in-house research and data organisation: Deerfield Intelligence is described as the firm's data, technology and AI arm, and Deerfield Discovery and Development (3DC) as its internal R&D engine, taking early-stage therapeutics from discovery through preclinical proof of concept into clinical development. Deerfield also builds companies with academic and health-system partners through named discovery alliances. It is an SEC-registered investment adviser (CRD 157876, SEC file 801-73284) and files quarterly 13F reports covering listed equities, ADSs and convertible notes, so its public-market activity sits alongside its private investing rather than replacing it.
View full Deerfield Management profile →Shenzhen Capital Group describes itself on its own site as a state-owned comprehensive investment group whose core business is venture capital, and says its business spans venture capital, real estate investment, public mutual funds and asset securitisation. Within venture capital it says it manages venture funds, funds of funds, S funds and buyout funds, and it has managed government guidance funds since setting up China's first government guidance sub-fund with the Suzhou municipal government in 2007 and taking on entrusted management of the Shenzhen municipal guidance fund from 2016. Chairman Zuo Ding stated in a 25 February 2026 article on the group's site that more than 85 per cent of the 1,800 plus companies the group has directly invested in are start-up stage or growth stage, that more than 90 per cent are hard technology companies, and that the focus areas cover semiconductors, robotics, new materials, biopharmaceuticals and industrial software. The group's investment departments are organised by both sector (information technology, high-end equipment, general equipment, new materials, new energy, biopharmaceuticals) and region (Greater Bay Area, North China, Northeast, Central China, Southeast, Jiangsu, Shanghai, West China). Its wholly owned subsidiary Red Soil Innovation Fund Management, set up in June 2014, was the first public mutual fund management company in China established by a private equity institution.
View full Shenzhen Capital Group profile →